The collection of these images is central to meeting ADNI’s objective of developing biomarkers to track both the progression of Alzheimer’s disease and changes in the underlying pathology. The table below represents an overview of the PET data collected throughout the ADNI study (see table superscript references in the following paragraph).
Florbetapir (AV-452) PET and FDG PET imaging is performed on all newly enrolled participants on two separate days (a minimum of 12 hours between scans is required). Scans may be performed in any order but both must be completed within two weeks before or two weeks after the in-clinic assessments at baseline and at the second annual visit, 24 months after baseline.
Due to funding limitations, EMCI5 participants carried forward from ADNI GO receive a total of two sets of Florbetapir PET and FDG PET imaging across ADNI GO and ADNI2. The timing of the initial Florbetapir PET and FDG PET scans under ADNI2 will be based on the date of the last Florbetapir and FDG PET scan under ADNI GO. Two years from that date will be the “initial” Florbetapir and FDG PET scan date under ADNI2.
For ADNI1 CN and MCI participants who continued into ADNI GO and then to ADNI2, initial PET scans occur two years from that date of the last successful Florbetapir and FDG PET scan under ADNI GO.
Note: When searching the database for baseline or “Timepoint 1″ data, users should select both “screening” and “baseline” from the visit selection box.
Available Image Data
Click to enlarge or download the PDF. Note that not all subjects will have every type of image data, depending on the study and acquisition site.
Study Update: PET
Patients in ADNI1 initially received PIB3 scans instead of Florbetapir scans. However, the protocol was amended before the conclusion of the study to include the adoption of Florbetapir scans over PIB scans due to processing time limits.